Johnson & Johnson (JNJ) news

Older JNJ news events, each with the realized, point-in-time move the market made — page 6 of 10. Back to the JNJ overview → · Full JNJ reaction history →

Latest news

Recent JNJ events, each with its measured reaction. (Page 6 of 10.)

DateHeadlineEventSource5-minTo close
Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare ConferencePress releaseBusiness Wire+1.46%+2.15%
Form 8-K JOHNSON & JOHNSON For: Apr 15SEC filing · Form 8-KSEC EDGAR-0.82%-1.72%
Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%Press releaseBusiness Wire-0.82%-1.72%
Johnson & Johnson Reports Q1 2025 ResultsPress releaseBusiness Wire-0.82%-1.72%
Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pillPress releasePR Newswire-0.69%-1.12%
Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)Press releasePR Newswire-1.08%-2.28%
Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare ConferencePress releaseBusiness Wire-1.08%-2.28%
TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritisPress releasePR Newswire-0.39%-3.97%
Form 8-K JOHNSON & JOHNSON For: Mar 31SEC filing · Form 8-KSEC EDGAR-0.39%-3.97%
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience LeadershipPress releaseBusiness Wire+0.11%+0.69%
Federal Judge Rejects Johnson & Johnson Bankruptcy Strategy, Paving Way for Talc Victims to Seek Justice in Trial CourtsPress releaseBusiness Wire-1.05%-5.16%
Johnson & Johnson Announces Expected Closing Date for Intra-Cellular AcquisitionPress releaseBusiness Wire+0.11%+0.69%
Johnson & Johnson to Return to Tort System to Defeat Meritless Talc ClaimsPress releaseBusiness Wire-1.05%-5.16%
Med One Announces the Hiring of Sheri Thomas as Chief Financial OfficerPress releasePR Web+0.14%+0.15%
New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)Press releasePR Newswire-0.04%+0.32%
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancerPress releasePR Newswire+0.08%+0.28%
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four YearsPress releaseBusiness Wire+0.12%+0.39%
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025Press releasePR Newswire-0.10%+0.01%
U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's diseasePress releasePR Newswire+0.12%+0.39%
Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designationPress releasePR Newswire+0.02%+0.50%
Form ARS JOHNSON & JOHNSON For: Dec 29SEC filing · Form ARSSEC EDGAR-0.34%-0.54%
Form DEF 14A JOHNSON & JOHNSON For: Mar 12SEC filing · Form DEFSEC EDGAR-0.34%-0.54%
Form DEFA14A JOHNSON & JOHNSONSEC filing · Form DEFA14ASEC EDGAR-0.34%-0.54%
Health Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancerPress releaseCanada Newswire+1.25%+0.13%
Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patientsPress releasePR Newswire+1.25%+0.13%
Six Dean Omar Branham Shirley Partners Honored for Representation of PlaintiffsPress releaseBusiness Wire-0.19%-0.80%
Icotrokinra results show potential to set a new standard of treatment in plaque psoriasisPress releasePR Newswire+1.25%+0.13%
Johnson & Johnson to Host Investor Conference Call on First-Quarter ResultsPress releaseBusiness Wire+0.22%+0.42%
Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor RelationsPress releaseBusiness Wire+0.73%+0.37%
Form CERT JOHNSON & JOHNSONSEC filing · Form CERTSEC EDGAR+0.09%+0.99%
Form 8-A12B JOHNSON & JOHNSONSEC filing · Form 8-A12BSEC EDGAR+0.05%+0.88%
Form 8-K JOHNSON & JOHNSON For: Feb 26SEC filing · Form 8-KSEC EDGAR+0.05%+0.88%
TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitisPress releasePR Newswire-0.07%+1.51%
Form 8-K JOHNSON & JOHNSON For: Feb 20SEC filing · Form 8-KSEC EDGAR-0.07%+1.51%
E.C. Schultek announces the release of his debut book, 'The Ten: Short Stories of Ten Business Leaders Who Left a Legacy'Press releasePR Web+0.11%+1.67%
Form 10-K JOHNSON & JOHNSON For: Dec 29SEC filing · Form 10-KSEC EDGAR-0.27%-0.72%
Form 13F-HR JOHNSON & JOHNSON For: Dec 31SEC filing · Form 13F-HRSEC EDGAR+0.00%-0.32%
New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseasesPress releasePR Newswire-0.17%+1.28%
Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare ConferencePress releaseBusiness Wire+0.31%+1.43%
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Johnson & Johnson (JNJ) and Encourages Shareholders to Learn More About the InvestigationPress releaseAccesswire+0.07%+0.03%
Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet NeurologyPress releasePR Newswire+0.20%+1.04%
Johnson & Johnson champions first-ever Canadian consensus paper identifying critical gaps in psoriasis care for patients with skin of colourPress releaseCanada Newswire+0.20%+1.04%
Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Shareholders to Inquire about Securities InvestigationPress releaseAccesswire+0.54%+1.89%
Form 8-K JOHNSON & JOHNSON For: Jan 22SEC filing · Form 8-KSEC EDGAR-0.38%+0.88%
Form 8-K/A JOHNSON & JOHNSON For: Jan 22SEC filing · Form 8-KSEC EDGAR+0.20%+1.04%
Johnson & Johnson Reports Q4 and Full-Year 2024 ResultsPress releaseBusiness Wire-0.38%+0.88%
Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Shareholders to ConnectPress releaseAccesswire+0.06%-0.17%
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depressionPress releasePR Newswire+0.48%+0.54%
Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Stockholders to Inquire about Securities InvestigationPress releaseAccesswire+0.48%+0.54%
Johnson & Johnson (JNJ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationPress releaseAccesswire-0.12%-0.43%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground